Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 588 participants.
Also called NCT01615198
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 588 participants
- Sponsor
- Registry
-
NCT01615198
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China, Hong Kong SAR China, Japan, Philippines, South Korea, Taiwan, Thailand
- Registry status
- Completed
Technical summary
Registry record NCT01615198. Randomized; double masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2013-07 (actual). Results posted on 2015-08-18.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension
- Condition
- Essential Hypertension
- Intervention (Drug)
- Olmesartan
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- LCZ696
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct01615198- Content hash
13e19005678a33722e03b3bf54d3efc2ac261b35c37f58f6e3cfbcea80a650b2